Wednesday, April 6, 2011

Fluidigm to get more milestone cash in Novartis diagnostics deal

Novartis Vaccines and Diagnostics will pay $320,000 more to Fluidigm Corp. if the South San Francisco company hits a milestone in its development of a non-invasive prenatal diagnostic test.
Novartis Vaccines and Diagnostics, whose diagnostics arm is based in Emeryville, now could make $3.32 million in milestone payments, according to amended deal outlined in a Securities and Exchange Commission filing Monday by Fluidigm.

No comments:

Post a Comment